Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

September 8th 2024, 6:25pm

IASLC World Conference on Lung Cancer

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Global Survey Examines Barriers to Optimal Lung Cancer Biomarker Testing

September 8th 2024, 1:07am

IASLC World Conference on Lung Cancer

Global surveys from 2018 and 2024 demonstrated barriers to optimizing biomarker testing for patients with early- or late-stage lung cancer.

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

September 7th 2024, 10:37pm

IASLC World Conference on Lung Cancer

A 12-mg/kg dose of ifinatamab deruxtecan improved efficacy compared with an 8-mg/kg dose in heavily pretreated patients with extensive-stage small cell lung cancer.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

September 7th 2024, 6:14pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

September 7th 2024, 4:52pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management

September 7th 2024, 12:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

September 6th 2024, 8:26pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Dr Seymour on the Role of Mutational Profiling in CLL

September 6th 2024, 6:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

John Seymour, MBBS, FRACP, PhD, discusses the role of genetic profiling in the treatment of chronic lymphocytic leukemia.

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

September 6th 2024, 6:09pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Liso-cel produced responses across subgroups of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

September 6th 2024, 5:27pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

September 6th 2024, 4:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

Improved OS, Cost Effectiveness Are Necessary to Shift Later-Line TKIs to Frontline CML-CP

September 6th 2024, 1:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Elias Jabbour, MD, discusses the potential activity and financial benefit of novel and emerging TKIs for first-line management of chronic phase CML.

Dr Merryman on the Evolution of MRD Assays in Lymphoma

September 5th 2024, 7:25pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

September 5th 2024, 7:25pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

September 5th 2024, 5:40pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Imetelstat Delivers Sustained RBC-TI With No OS Detriment in Lower-Risk MDS

September 5th 2024, 5:14pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Imetelstat sustained red blood cell (RBC) transfusion independence in patients with RBC transfusion–dependent lower-risk myelodysplastic syndrome.

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

September 5th 2024, 1:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Reid W. Merryman, MD, discusses notable advancements with minimal residual disease assays in lymphoma.

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL

September 4th 2024, 9:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma

September 4th 2024, 9:20pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Dr Giralt on Determining Transplant Eligibility in MDS

September 4th 2024, 9:12pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.